Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
暂无分享,去创建一个
G. Jerusalem | P. Rigo | G. Fillet | P. Paulus | Y Beguin | P Rigo | Y. Beguin | G Jerusalem | M F Fassotte | F Najjar | P Paulus | G Fillet | M. Fassotte | F. Najjar | Y. Beguin
[1] W. Murphy,et al. Radiation fibrosis: differentiation from recurrent tumor by MR imaging. , 1985, Radiology.
[2] I. Magrath,et al. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D Front,et al. Gallium 67 imaging in monitoring lymphoma response to treatment , 1988, Cancer.
[4] S. Kvaløy,et al. Magnetic resonance imaging and 67gallium scan in mediastinal malignant lymphoma: a prospective pilot study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] P. Hoffer,et al. The role of gallium-67 in the clinical evaluation of cancer. , 1984, Seminars in nuclear medicine.
[6] A. Wolf,et al. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] S M Larson,et al. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] C. Zuiani,et al. Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. , 1996, Magma.
[9] F. Gherlinzoni,et al. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. , 1996, Leukemia & lymphoma.
[10] T. Hickish,et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Al-Katib,et al. Lymphomas: MR imaging contrast characteristics with clinical-pathologic correlations. , 1990, Radiology.
[12] K. Ho,et al. Diffuse thymic hyperplasia following chemotherapy for nodular sclerosing Hodgkin's disease: An immunologic rebound phenomenon? , 1983, Cancer.
[13] B. Glimelius,et al. Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging. , 1989, Radiology.
[14] A. Santoro,et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] P. Stomper,et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Belakhlef,et al. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] G. Canellos,et al. Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] O. Israel,et al. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. , 1995, Seminars in nuclear medicine.
[19] D. Bumann,et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] R. Hardoff,et al. Uptake of gallium-67 citrate and [2-3H]deoxyglucose in the tumor model, following chemotherapy and radiotherapy. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.